ImmunoForge, a clinical-stage biopharmaceutical company specialising in treatments for rare and muscular diseases, is poised to redefine central nervous system (CNS) drug delivery with its proprietary LMT15 Platform, a next-generation blood-brain barrier (BBB) shuttle technology.
The LMT15 Platform is based on leptin receptor-mediated transcytosis (LMT), offering a significant competitive edge over existing BBB penetration technologies. By leveraging this specific pathway, LMT15 achieves superior permeability into the brain while minimising potential side effects.
A key differentiator of LMT15 is its integration with ImmunoForge’s core ELP (elastin-like polypeptide) technology. This unique fusion allows for a single-structure modality that provides both efficient BBB penetration and a once-monthly long-acting formulation. This dual-functionality is expected to have transformative applications in the development of CNS-targeted therapies and long-acting obesity medications.
The innovative potential of LMT15 was recently recognized on a global stage. ImmunoForge announced that it was awarded first place at ‘Novo Nordisk Partnering Day 2026’, an open innovation event co-hosted by Novo Nordisk Pharma Korea, the Korea Health Industry Development Institute (KHIDI), and Novo Holdings on 1 April. Out of numerous domestic biotech and healthcare participants, ImmunoForge secured the top spot following a rigorous preliminary review and final pitching session.
As a winner, ImmunoForge will receive expert feedback, investment mentoring, and collaboration networking opportunities from Novo Nordisk and Novo Holdings, further validating its technological prowess and market readiness.
Earlier this year, ImmunoForge filed for a patent for LMT15 and is now initiating full-scale development for its CNS pipeline.
